Therapeutic Strategies for Targeting Angiogenesis in TME
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology offers a full range of solutions and services for investigating therapeutic strategies that for target angiogenesis in the tumor microenvironment (TME), helping researchers successfully achieve their research goals.
Tumor growth and metastasis depend on the tumor vascular network to provide adequate oxygen and nutrients. The molecular mechanisms regulating tumor angiogenesis are complex and require the mediation of many growth factors, receptors and signaling pathways, such as growth factor dependent signaling, endothelial cell (EC) proliferation, extracellular matrix (ECM) remodeling and stromal cell interactions. Although many targeted antiangiogenic drugs have been marketed or are being developed, some have shown poor clinical outcomes and some have resistance problems, which may result from the multiple regulatory pathways of tumor vascularization.
Fig. 1 Angiogenesis signaling and targets of inhibition in approved antiangiogenic agents. (Zhao Y, Adjei A A, 2015)
Abbreviations: Ang, angiopoietin; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PlGF, placental growth factor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
Understanding the molecular regulatory mechanisms associated with tumor vasculature and exploring possible antitumor targets in the angiogenesis chain is the key to solving the current problems of targeting tumor angiogenesis drugs and helping to propose new strategies for tumor vascular research.
Alfa Oncology has established an innovative tumor microenvironment center technology platform and is developing several technologies designed to help global collaborators develop therapeutic strategies targeting angiogenesis in tumor microenvironment (TME). We are vigorously developing novel multi-targeted drugs, with clinical emphasis on the integration of molecular targets, and conducting in-depth research on therapeutic strategies targeting angiogenesis to provide clues and basis for individualized precision therapy.
Alfa Oncology offers key strategies for targeting extracellular matrix (ECM) including but not limited to:
- Anti-VEGF (vascular endothelial growth factor) / VEGFR (vascular endothelial growth factor receptor)
Tumor angiogenesis can be blocked by angiogenesis inhibitors. The goal of these drugs (also called anti-angiogenic agents) is to prevent or slow the growth of cancer by making it lack the needed blood supply. Among many angiogenic factors, VEGF is the most potent and plays a crucial regulatory role in the process of angiogenesis. VEGF and VEGFR are highly expressed in both tumor cells and tumor vascular endothelium and are the most ideal targets for anti-tumor angiogenesis. Such as: Bevacizumab.
- Small molecule multi-target tyrosine kinase inhibitors
This class of drugs is a small molecule multi-targeted anti-angiogenic inhibitor with diverse mechanisms of action. Not only anti-angiogenesis, but also other effects, such as inhibition of tumor cell growth and proliferation.
- Recombinant human vascular endothelial inhibitor
It mainly acts on the endothelial cells of tumor vessels, and this class of drugs usually requires intravenous administration, and has been in the clinic for many years.
Note: The key strategies we focus on are always up to date, please contact us by email for more up-to-date and relevant information.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.
- Zhao Y, Adjei A A. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor[J]. The Oncologist, 2015, 20(6):660-673.